ArticleArchives of medical science : AMS2025
Gut microbiota and arterial hypertension: a narrative review.
Article in Archives of medical science : AMS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gut Microbiota in Metabolic Syndrome: Differences in Microbial Signatures and Clinical Profiles.Medicina (Kaunas, Lithuania) · 2026Review
- High Salt Intake and Atherosclerosis Progression-Not Only via Blood Pressure: A Narrative Review.Nutrients · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In patients with hypertension, intestinal dysbiosis and increased intestine permeability are commonly observed. Modifications of intestinal microbiota with certain probiotics, prebiotics, and synbiotics, as well as gut microbiota transfer, have been associated with a reduction in blood pressure. Therefore, these interventions, especially probiotics, can be employed as adjuncts to hypertension therapy. Bacteria constituting dysbiotic intestinal microbiota produce compounds with hypertensinogenic activity (trimethylamine - TMA, pathogen-associated molecular patterns - PAMPs). In addition, in a state of dysbiosis, a decrease in the production of compounds with antihypertensive activity (short-chain fatty acids - SCFAs) is observed. A diet high in salt significantly alters the intestinal microbiota, and such dysbiosis has been implicated in the pathogenesis of salt-sensitive hypertension. This narrative review article discusses the importance of the gut microbiota, its dysbiosis in patients with hypertension, and potential therapeutic options.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.